Cargando…

Screening and evaluation of approved drugs as inhibitors of main protease of SARS-CoV-2

The COVID-19 pandemic caused by SARS-CoV-2 has emerged as a global catastrophe. The virus requires main protease for processing the viral polyproteins PP1A and PP1AB translated from the viral RNA. In search of a quick, safe and successful therapeutic agent; we screened various clinically approved dr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tripathi, Praveen Kumar, Upadhyay, Saurabh, Singh, Manju, Raghavendhar, Siva, Bhardwaj, Mohit, Sharma, Pradeep, Patel, Ashok Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444494/ https://www.ncbi.nlm.nih.gov/pubmed/32853604 http://dx.doi.org/10.1016/j.ijbiomac.2020.08.166

Ejemplares similares

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors
por: Jiménez-Alberto, Alicia, et al.
Publicado: (2020)

In silico screening of FDA approved drugs reveals ergotamine and dihydroergotamine as potential coronavirus main protease enzyme inhibitors
por: Gurung, Arun Bahadur, et al.
Publicado: (2020)

In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus
por: Eleftheriou, Phaedra, et al.
Publicado: (2020)

Computer Aided Drug Design Approach to Screen Phytoconstituents of Adhatoda vasica as Potential Inhibitors of SARS-CoV-2 Main Protease Enzyme
por: Siva Kumar, Bathula, et al.
Publicado: (2022)

Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery
por: Ray, Abhik Kumar, et al.
Publicado: (2022)

Virtual screening and repurposing of FDA approved drugs against COVID-19 main protease
por: Kandeel, Mahmoud, et al.
Publicado: (2020)

Screening of FDA Approved Drugs Against SARS-CoV-2 Main Protease: Coronavirus Disease
por: Balakrishnan, Vijayakumar, et al.
Publicado: (2020)

Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease
por: Gupta, Akshita, et al.
Publicado: (2020)

Rapid structure-based identification of potential SARS-CoV-2 main protease inhibitors
por: Sobhia, M Elizabeth, et al.
Publicado: (2021)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

An in-silico evaluation of COVID-19 main protease with clinically approved drugs
por: Tachoua, Wafa, et al.
Publicado: (2020)

Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach
por: Gupta, Yash, et al.
Publicado: (2021)

Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies
por: Verma, Dipesh Kumar, et al.
Publicado: (2022)

Targeting the nsp2 Cysteine Protease of Chikungunya Virus Using FDA Approved Library and Selected Cysteine Protease Inhibitors
por: Kumar, Prateek, et al.
Publicado: (2019)

Evaluation of acridinedione analogs as potential SARS-CoV-2 main protease inhibitors and their comparison with repurposed anti-viral drugs
por: Bhardwaj, Vijay Kumar, et al.
Publicado: (2021)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Virus load and clinical features during the acute phase of Chikungunya infection in children
por: B., Siva Raghavendhar, et al.
Publicado: (2019)

Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease
por: OKTAY, Lalehan, et al.
Publicado: (2021)

Computational investigation of natural compounds as potential main protease (M(pro)) inhibitors for SARS-CoV-2 virus
por: Patel, Chirag N., et al.
Publicado: (2022)

Screening of Potent Phytochemical Inhibitors Against SARS-CoV-2 Main Protease: An Integrative Computational Approach
por: Mahmud, Shafi, et al.
Publicado: (2021)

Apigenin analogues as SARS-CoV-2 main protease inhibitors: In-silico screening approach
por: Farhat, Ameny, et al.
Publicado: (2022)

High-throughput screening of SARS-CoV-2 main and papain-like protease inhibitors
por: Zang, Yi, et al.
Publicado: (2022)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

Plant-Based Phytochemical Screening by Targeting Main Protease of SARS-CoV-2 to Design Effective Potent Inhibitors
por: Mahmud, Shafi, et al.
Publicado: (2021)

Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents
por: Ahmed, Mohammad Z., et al.
Publicado: (2021)

Screening, Purification and Characterization of Protease Inhibitor from Capsicum frutescens
por: Mohan, Manju, et al.
Publicado: (2018)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease
por: Marinho, Emanuelle Machado, et al.
Publicado: (2020)

Fenoterol and dobutamine as SARS-CoV-2 main protease inhibitors: A virtual screening study
por: Bolelli, Kayhan, et al.
Publicado: (2021)

High Throughput Virtual Screening to Discover Inhibitors of the Main Protease of the Coronavirus SARS-CoV-2
por: Olubiyi, Olujide O., et al.
Publicado: (2020)

Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening
por: Hakami, Abdulrahim R, et al.
Publicado: (2021)

In silico Screening of Potential SARS-CoV-2 Main Protease Inhibitors from Thymus schimperi
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2023)

Molecular docking and dynamics simulation of FDA approved drugs with the main protease from 2019 novel coronavirus
por: Odhar, Hasanain Abdulhameed, et al.
Publicado: (2020)

In silico molecular docking analysis for repurposing approved antiviral drugs against SARS-CoV-2 main protease
por: Khater, Ibrahim, et al.
Publicado: (2021)

Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors
por: Kim, Hoshin, et al.
Publicado: (2022)

In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
por: Kumar, Yogesh, et al.
Publicado: (2020)

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
por: Mahdi, Mohamed, et al.
Publicado: (2020)

Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
por: Prajapat, Manisha, et al.
Publicado: (2020)

Review on development of potential inhibitors of SARS-CoV-2 main protease (M(Pro))
por: Katre, Soumya Gulab, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qtnnsqnh5tb9rkg8dtqpd3crh2